Tardive Dyskinesia Clinical Trial
Official title:
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
Extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) are one of the most frequent and troublesome adverse events when taking antipsychotic agents. The investigators aim in this study to determine if the investigators can conduct examinations for EPS and TD remotely using live two-way video. It is potentially beneficial for patients, especially those who are located far away from psychiatrists if they could be seen by trained clinicians and assessed for EPS and TD via two-way video in the future. Participants will be asked to have a medical assessment which consists of simple questions and some examination of their movements via two-way video and in person. The investigators will compare the results of video examinations with the results of live examinations. ;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02840760 -
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
|
N/A | |
Completed |
NCT01688037 -
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
|
Phase 2 | |
Completed |
NCT01391390 -
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
|
N/A | |
Withdrawn |
NCT03254186 -
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02291861 -
Addressing Involuntary Movements in Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02274558 -
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02198794 -
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT04794413 -
Pimavanserin Treatment in TS
|
Early Phase 1 | |
Recruiting |
NCT06011408 -
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
|
N/A | |
Recruiting |
NCT05859698 -
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
|
Phase 4 | |
Active, not recruiting |
NCT02252380 -
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
|
N/A | |
Terminated |
NCT00917293 -
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
|
Phase 2 | |
Completed |
NCT01543321 -
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
|
Phase 3 | |
Completed |
NCT02405091 -
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03176771 -
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Terminated |
NCT02524886 -
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
|
N/A | |
Completed |
NCT02195700 -
Aim to Reduce Movements in Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02736955 -
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03497013 -
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
|
N/A | |
Withdrawn |
NCT01908452 -
Pyridoxal Kinase Activity in Tardive Dyskinesia
|
Phase 3 |